Literature DB >> 3315269

Treatment of asthma by a controlled-release theophylline tablet formulation: a review of the North American experience with nocturnal dosing.

P D Goldenheim1, E A Conrad, L K Schein.   

Abstract

As many as 80 percent of asthmatics experience nighttime or early-morning episodes, which are difficult to treat and potentially fatal. The greater-than-normal amplitude of circadian airflow variation in many asthmatics contributes heavily to the genesis of the early 'morning dip'. Beta-agonists and corticosteroids are of limited usefulness in nocturnal asthma, and slow-release theophylline drugs, while potentially effective, vary in 24-hr blood profile and hence their influence on nocturnal episodes. Traditional 12-hr 'symmetric' theophylline regimens, instead of meeting increased nocturnal demands, may actually produce lower night- than daytime blood levels. On the other hand, appropriately timed administration of a once-daily theophylline drug might provide maximum blood levels when needed and help stabilize 24-hr airflow. Accumulated data, summarized in this review, demonstrate the chronotherapeutic potential of single-daily evening doses of a controlled-release theophylline preparation (Uniphyl 400-mg tablets) in nocturnal and early morning asthma. Nighttime blood concentrations with this regimen were higher than were those with Theo-Dur tablets, B.I.D., in the same total daily doses, or with once-daily morning Uniphyl administration. In fed and fasted subjects, evening administration of Uniphyl 400-mg tablets was well tolerated and did not lead to 'dose dumping.' Clinically, this treatment demonstrated advantages over B.I.D. theophylline, over single-daily morning regimens, and over prior theophylline therapy. Advantages of the evening regimen included better early-morning airflow (without significant decline later in the day), more effective symptom control, better patient acceptance, fewer night awakenings, and the obvious convenience of once-daily dosing. In addition, lung function showed greater stability, throughout the day, with once-daily evening therapy than with traditional 12 hr dosing. Uniphyl 400-mg tablets may be administered once daily to provide maximum blood levels at the time of peak bronchoconstriction, whether at night or during the day.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3315269     DOI: 10.3109/07420528709083529

Source DB:  PubMed          Journal:  Chronobiol Int        ISSN: 0742-0528            Impact factor:   2.877


  3 in total

Review 1.  Chronopharmacology and its application to the development of theophylline treatment schedules for asthma.

Authors:  K R Godfrey
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 2.  Nocturnal asthma: underlying mechanisms and treatment.

Authors:  E Rand Sutherland
Journal:  Curr Allergy Asthma Rep       Date:  2005-03       Impact factor: 4.806

3.  An organic acid-induced sigmoidal release system for oral controlled-release preparations.

Authors:  S Narisawa; M Nagata; C Danyoshi; H Yoshino; K Murata; Y Hirakawa; K Noda
Journal:  Pharm Res       Date:  1994-01       Impact factor: 4.200

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.